2 active not recruiting, 1 available, 1 completed, 1 recruiting. 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 2 | Active not recruiting 2 |
Follow dodecyl maltoside: new trials by email Literature Review of dodecyl maltoside trials Research Report on dodecyl maltoside
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside - Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer | Phase 2 | Recruiting | Lepu Biopharma Co., Ltd. | 16 | 2025-12-04 | 2026-04-23 |
| A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside - Non Muscle Invasive Bladder Cancer, Urologic Cancer | Phase 3 | Active not recruiting | CG Oncology, Inc. | 367 | 2023-12-14 | 2026-07-01 |
| Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin CG0070, Pembrolizumab Injection, n-dodecyl-B-D-maltoside - Non Muscle Invasive Bladder Cancer | Phase 2 | Completed | CG Oncology, Inc. | 35 | 2020-12-08 | 2024-09-25 |
| Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside - Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer | Phase 3 | Active not recruiting | CG Oncology, Inc. | 190 | 2020-10-27 | 2026-07-10 |
| An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside - Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma | Available | CG Oncology, Inc. | 2026-09-11 |
Non-Muscle Invasive Bladder Neoplasms (5) · Carcinoma in Situ (3) · Carcinoma, Transitional Cell (2) · Urinary Bladder Neoplasms (2) · Urologic Neoplasms (2)
CG Oncology, Inc. (4) · Lepu Biopharma Co., Ltd. (1)
United States (4) · Canada (2) · South Korea (2) · Australia (1) · China (1) · Japan (1) · Taiwan (1)
Max Kates, MD (1)